MedTrace Logo

Efficacy and Safety of IBI-10090 in Ocular Surgery Patients

NCT01606735 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2014-09-22

Study results available
· View outcomes & findings →

Summary

This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.

Conditions

  • Inflammation Associated With Cataract Surgery

Interventions

DRUG

IBI-10090

dexamethasone

Sponsors & Collaborators

  • ICON Bioscience Inc

    lead INDUSTRY

Principal Investigators

  • Wendy Murahashi, MD · Sponsor GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01606735 on ClinicalTrials.gov